glp-1 receptor agonists in pediatric and adolescent obesity diabetes: a systematic review of efficacy, metabolic effects, and safety Metabolic outcomes and safety of

Liraglutide was approved by the FDA for marketing in the United States in 2010 and officially launched in China in 2011

Multiple mechanisms have been proposed to explain these observations, though the precise pathways remain an active area of research

In a phase 1 double-blind randomized study, in which participants either received LY3298176 or a placebo, Coskun et al

GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO Study

There were no ICP lowering agents or addition of headache preventative drugs started during the study

Physical activity represents a potent, evidence-based intervention for enhancing metabolic health through multiple mechanisms, including improved insulin sensitivity, glucose utilization, and cardiovascular function